Risultati della ricerca - S.R. Schwid

  • Mostra 1 - 5 risultati su 5
Raffina i risultati
  1. 1
    Cost-effectiveness of disease-modifying therapy for multiple sclerosis

    Cost-effectiveness of disease-modifying therapy for multiple sclerosis di Katia Noyes, Alina Bajorska, A T Chappel, S. R. Schwid, Lahar Mehta, Bianca Weinstock‐Guttman, Robert G. Holloway, Andrew W. Dick

    Pubblicazione 2011
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  2. 2
    Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis

    Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis di Steven R. Schwid, John Thorpe, Mohammad K. Sharief, Magnhild Sandberg‐Wollheim, Kottil Rammohan, Jeanette Wendt, Hillel S. Panitch, Douglas S. Goodin, David Li, Peter Chang, Gordon Francis

    Pubblicazione 2005
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  3. 3
    Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis

    Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis di Lauren Krupp, Christopher Christodoulou, Patricia Melville, W. F. Scherl, L.-Y. Pai, L.R. Muenz, Dian He, R.H.B. Benedict, Andrew Goodman, Syed Rizvi, S.R. Schwid, Bianca Weinstock‐Guttman, Holly James Westervelt, H. Wishart

    Pubblicazione 2011
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease

    Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease di Michael A. Schwarzschild, Steven R. Schwid, Kenneth Marek, Arthur Watts, Anthony E. Lang, David Oakes, Ira Shoulson, Alberto Ascherio, Christopher Hyson, Emily Gorbold, Alice Rudolph, Karl Kieburtz, Stanley Fahn, Lisa Gauger, Christopher G. Goetz, John Seibyl, M. Forrest, John Ondrasik

    Pubblicazione 2008
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials

    Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials di Andrew Goodman, François Béthoux, Theodore R. Brown, Randall T. Schapiro, Ron Cohen, Lawrence N. Marinucci, Herbert R. Henney, Andrew R. Blight, Mark Agius, B. G. W. Arnason, F. Béthoux, C. T. Bever, JD Bowen, TR Brown, D. Dietrich, Kelly Edwards, MS Freedman, Mark S. Freedman, NJ Kachuck, MD Kaufman, Marshall J. Keilson, Omar Khan, Lauren Krupp, TP Leist, John Lindsey, F.D. Lublin, MK Mass, D. E. Mattson, Denise McGowan, Robert T. Naismith, Colleen O’Connell, JJ Oger, Hillel S. Panitch, MA Picone, K Rammohan, RT Schapiro, S.R. Schwid, Thomas F. Scott, C Short, BW Thrower, TL Vollmer, Ann Camac, JA Cooper, WF Chumley, Anne H. Cross, RT Dunnigan, JS Gitt, Marij A. Hillen, DR Jeffrey, B. Khatri, Kiren Kresa-Reahl, Seok Whan Moon, Jana Lízrová Preiningerová, Mark Tullman, Bianca Weinstock‐Guttman, DR Wynn

    Pubblicazione 2015
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: